China NMPA approves Keymed Biosciences’ sNDA for Stapokibart to treat chronic rhinosinusitis with nasal polyposis: Chengdu, China Thursday, December 26, 2024, 18:00 Hrs [IST] Ke ...
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of patients with ...
Experiencing chronic sinusitis, hearing loss, ear infections, sore throats, or colds that lasts more than a week or keeps coming back? Then it’s time to see an otolaryngologist. An otolaryngologist or ...